IPM Take
Personalised oncology cannot only mean matching the right therapy to the right tumour. It must also mean keeping the patient well enough to receive and survive that therapy. ESC Cardio-Oncology 2026 showed that established heart failure treatments, especially RAAS inhibitors and beta-blockers, may help protect cardiac function in patients receiving anticancer treatment. But the evidence is still uneven, particularly for newer heart failure therapies. The policy message is blunt: cancer innovation is moving faster than cardio-oncology infrastructure. If health systems do not build risk assessment, monitoring and referral pathways around cardiotoxicity, the promise of precision oncology will keep colliding with preventable cardiac harm.
Executive Summary
At ESC Cardio-Oncology 2026 in Vienna, researchers presented new evidence on medical therapies that may protect the heart from anticancer drug-related cardiac dysfunction. A systematic review and meta-analysis identified 49 studies involving 6,998 patients treated with anticancer therapies. The analysis found that renin-angiotensin-aldosterone system inhibitors, beta-blockers and statins were associated with improvements in left ventricular ejection fraction, a measure of cardiac pumping function. The strongest signal among well-studied strategies was seen with the combination of RAAS inhibition and beta-blockers. However, evidence for newer heart failure agents, including mineralocorticoid receptor antagonists and SGLT2 inhibitors, remains limited because only a small number of studies were available. The findings strengthen the case for cardio-oncology pathways, but they also expose a familiar implementation gap: patients receiving modern cancer treatment need systematic cardiovascular risk protection, not ad hoc referral after damage appears.
Why it matters
- Clinicians: Cardiologists and oncologists need clearer pathways for preventing, detecting and managing cancer therapy-related cardiac dysfunction.
- Hospitals / providers: Cardio-oncology requires structured services, imaging capacity, biomarker monitoring, referral rules and multidisciplinary coordination.
- Payers: Reimbursement models should recognise cardiac protection as part of safe cancer treatment, not as a separate downstream complication.
- Policymakers: Cancer strategies that focus only on drug access risk missing the cardiovascular infrastructure needed to keep patients on treatment safely.
- Patients: Better cardiac monitoring and prevention may help patients continue effective cancer therapy while reducing avoidable heart damage.
Cancer treatment has changed fast.
Cardiac protection has not kept pace.
That is the uncomfortable message emerging from ESC Cardio-Oncology 2026, held in Vienna on 19-20 June 2026.
At the meeting, researchers from Erasmus University Medical Centre presented a systematic review and meta-analysis examining whether heart failure therapies can protect cardiac function in patients receiving anticancer drugs. The analysis brought together 49 studies involving 6,998 patients.
The question was practical.
When cancer therapies damage the heart, can established cardiovascular medicines help protect patients?
The answer appears to be yes, but with important caveats.
The analysis focused mainly on left ventricular ejection fraction, or LVEF, a common measure of how well the heart pumps blood. Across 23 studies assessing renin-angiotensin-aldosterone system inhibitors, LVEF improved by 2.88% compared with placebo or standard care. Across 22 beta-blocker studies, LVEF improved by 1.20%. The strongest signal among well-studied approaches came from the combination of RAAS inhibitors and beta-blockers, with LVEF improving by 2.98%.
Statins also showed a positive signal, with an LVEF increase of 2.49% compared with controls.
These are not experimental futuristic medicines. They are established cardiovascular therapies already used widely in heart failure and cardiovascular prevention. That is what makes the finding important for policy. The issue may not be whether cardiology has tools to help some cancer patients. The issue is whether health systems deploy them early, consistently and intelligently.
But the evidence is not equally strong across all therapies.
Mineralocorticoid receptor antagonists appeared encouraging, with an LVEF increase of 4.68%, but this was based on only two studies. SGLT2 inhibitors showed an LVEF improvement of 3.20%, but the evidence came from one study. ESC stressed that more randomised trials are needed, especially for newer cardiovascular treatments.
That caution matters.
Cardio-oncology is not a place for careless extrapolation. Cancer patients are not generic heart failure patients. Their cardiovascular risk depends on baseline heart health, cancer type, treatment regimen, cumulative dose, radiotherapy exposure, age, kidney function, metabolic risk, frailty and survivorship stage. Some patients need prevention before treatment starts. Others need monitoring during treatment. Others present later with cardiac dysfunction after therapy has already caused damage.
That is why personalised medicine matters here.
The relevant question is not simply: “Which heart drug protects against cardiotoxicity?”
The better question is: “Which cancer patient, receiving which therapy, with which baseline cardiovascular risk, needs which protection strategy, and when?”
That is a pathway question.
It requires risk assessment before cancer treatment begins. It requires echocardiography, biomarkers or other monitoring tools where appropriate. It requires oncologists and cardiologists to agree when to continue, pause or modify cancer therapy. It requires primary care and survivorship teams to know who needs long-term follow-up after cancer treatment ends.
Without those systems, cardioprotection becomes random.
Patients treated in major academic centres may receive cardio-oncology assessment. Patients in smaller hospitals or fragmented systems may only see cardiology after symptoms appear. That creates a predictable access gap: those with the strongest specialist pathways get prevention, while others get rescue care.
The stakes are high because cancer outcomes are improving.
As more patients survive cancer, cardiovascular disease becomes a larger part of the survivorship burden. Some patients may live long enough for treatment-related cardiac injury to become one of their major health threats. Others may have cancer therapy interrupted because cardiac dysfunction develops during treatment.
That is where oncology innovation runs into system reality.
A precision cancer drug that cannot be safely continued because cardiac risk was not managed is not a full success. It is a partial victory with a preventable failure built in.
For industry, the implication is also clear.
Cancer therapy development increasingly needs cardiovascular evidence. Trial programmes may need stronger baseline cardiac assessment, toxicity monitoring and survivorship endpoints. Cardioprotective co-management may become part of the value story, especially for treatments with known or suspected cardiac risks.
For payers, the question is whether cardio-oncology support should be funded as part of cancer care. If cardiac monitoring prevents treatment interruption, hospitalisation or long-term heart failure, it is not an optional extra. It is part of delivering the cancer therapy safely.
ESC Cardio-Oncology 2026 did not provide the final answer.
It provided a signal.
Established heart failure drugs may help protect the hearts of patients receiving anticancer therapy. But evidence gaps remain, especially for newer agents. And the bigger challenge is implementation.
Modern oncology is becoming more precise.
Now cardiology has to be built into that precision.
Because the future of cancer care is not only about attacking the tumour.
It is also about protecting the heart that has to carry the patient through treatment and survival.
